Sugi Predict

Sugi Predict / Compounds / SCHEMBL1653140

SCHEMBL1653140

SCHEMBL1653140

CCOC(=O)c1cc2c(C)ccc([N+](=O)[O-])c2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FBP1 P09467 8/20 0.49
▸ KMT2A Q03164 3/20 0.43
▸ CDK1 P06493 1/20 0.42
▸ CCNB1 P14635 1/20 0.42
▸ ALDH1A1 P00352 5/20 0.42
▸ RAB9A P51151 3/20 0.42
▸ HPGD P15428 3/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ MAPT P10636 3/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ PKM P14618 1/20 0.42
▸ CRHBP P24387 1/20 0.42
▸ CRHR2 Q13324 1/20 0.42
▸ LMNA P02545 3/20 0.41
▸ POLB P06746 2/20 0.41
▸ GALR2 O43603 1/20 0.41
▸ MITF O75030 1/20 0.41
▸ HSP90AA1 P07900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1653459 0.89 FBP1 (0.48) FBP1KMT2ACDK1CCNB1ALDH1A1
SCHEMBL7665395 0.88 FBP1 (0.53) FBP1KMT2ACDK1CCNB1ALDH1A1
SCHEMBL26844267 0.88 FBP1 (0.47) FBP1KMT2ACDK1CCNB1ALDH1A1
SCHEMBL1653841 0.85 FBP1 (0.42) FBP1KMT2ACDK1CCNB1ALDH1A1
SCHEMBL28460041 0.83 FBP1 (0.73) FBP1KMT2ACDK1CCNB1MAPT
SCHEMBL4042473 0.83 ALDH1A1 (0.50) KMT2ACDK1CCNB1ALDH1A1RAB9A
SCHEMBL28461385 0.83 FBP1 (0.62) FBP1KMT2AALDH1A1RAB9AKDM4E
SCHEMBL7665437 0.82 CDK1 (0.54) FBP1KMT2ACDK1CCNB1ALDH1A1
SCHEMBL28467727 0.82 CDK1 (0.43) FBP1KMT2ACDK1CCNB1ALDH1A1
SCHEMBL2767476 0.82 FBP1 (0.64) FBP1HPGDKDM4EMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190821-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF TRIANA BIOMEDICINES INC (US) 2024-06-13 — — US disclosed
WO-2022169755-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF TRIANA BIOMEDICINES, INC. (US) 2022-08-11 — — WO disclosed
WO-2022169755-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF TRIANA BIOMEDICINES, INC. (US) 2022-08-11 — — WO disclosed
US-8957070-B2 Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-02-17 — — US disclosed
EP-1873144-B1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL (JP) 2014-07-23 — — EP disclosed
US-8410087-B2 Indole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-04-02 — — US disclosed
EP-2508524-A2 Indole compound Takeda Pharmaceutical Company Limited (JP) 2012-10-10 — — EP disclosed
EP-2308839-A1 Fused heterocyclic compounds Takeda Pharmaceutical Company Limited (JP) 2011-04-13 — — EP disclosed
US-7834049-B2 Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-11-16 — — US disclosed
US-20100267754-A1 INTEGRIN EXPRESSION INHIBITOR WAKABAYASHI TOSHIAKI 2010-10-21 — — US disclosed
US-20050176712-A1 Integrin expression inhibitor EISAI CO., LTD. 2005-08-11 — — US disclosed
US-20040018192-A1 Integrin expression inhibitors EISAI CO., LTD. (JP) 2004-01-29 — — US disclosed
US-6673787-B2 PYRIMIDINESULFONAMIDE CONTAINING INDOLE COMPOUNDS USED AS ANTIANGIOGENIC AND ANTITUMOR AGENTS EISAI CO., LTD. (JP) 2004-01-06 — — US disclosed
US-6638964-B2 Pyridinesulfonamide containing indole compounds used as antiangiogenic and antitumor agents EISAI CO., LTD. (JP) 2003-10-28 — — US disclosed
CN-1396833-A Integrin expression inhibitors EISAI CO LTD (JP) 2003-02-12 — — CN disclosed
EP-1258252-A1 INTEGRIN EXPRESSION INHIBITORS Eisai Co., Ltd. (JP) 2002-11-20 — — EP disclosed
US-6469043-B1 ANTIANGIOGENIC AGENT WITH ANTITUMOR, ANTIMETASTATIC PROPERTIES WHICH SHOWS HIGH SAFETY EISAI CO., LTD. (JP) 2002-10-22 — — US disclosed
US-20020128483-A1 Sulfonamide-containing indole compounds EISAI CO., LTD. 2002-09-12 — — US disclosed
US-20020128480-A1 Sulfonamide-containing indole compounds EISAI CO., LTD. 2002-09-12 — — US disclosed
EP-1074542-A1 SULFONAMIDE-CONTAINING INDOLE COMPOUNDS Eisai Co., Ltd. (JP) 2001-02-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176712-A1 Integrin expression inhibitor ITGB5, ITGB1, ITGB2 FBP1 3805/4885KMT2A 2009/4885CDK1 386/4885
US-20020128480-A1 Sulfonamide-containing indole compounds IDO1, HCCS, VEGFA FBP1 2343/4885KMT2A 612/4885CDK1 72/4885
US-20240190821-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF PACSIN2, TPX2, PRSS12 FBP1 2679/4885KMT2A 4619/4885CDK1 2718/4885
US-20100267754-A1 INTEGRIN EXPRESSION INHIBITOR ITGB5, ITGB1, ITGB2 FBP1 3805/4885KMT2A 2009/4885CDK1 386/4885
US-20020128483-A1 Sulfonamide-containing indole compounds IDO1, HCCS, VEGFA FBP1 2450/4885KMT2A 564/4885CDK1 97/4885
US-20040018192-A1 Integrin expression inhibitors ITGB1, ITGB4, ITGB5 FBP1 3525/4885KMT2A 2523/4885CDK1 443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.